Tomoyuki Mizuno
Field Service Associate Professor-Affiliate
Childrens Hospital Bldg R
COM Pediatrics Clinical Pharmacology - 0054
Publications
Peer Reviewed Publications
Hahn D.;Fukuda T.;Euteneuer J.C.;Mizuno T.;Vinks A.A.;Sadhasivam S.;Emoto C. (08-01-2020. ) Influence of MRP3 Genetics and Hepatic Expression Ontogeny for Morphine Disposition in Neonatal and .Journal of Clinical Pharmacology, , 60 (8 ) ,992-998 More Information
van Hoogdalem M.W.;Emoto C.;Fukuda T.;Mizuno T.;Mehta P.A.;Vinks A.A. (05-01-2020. ) Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric.British Journal of Clinical Pharmacology, , 86 (5 ) ,933-943 More Information
Bauman L.E.;Xiong Y.;Mizuno T.;Minar P.;Fukuda T.;Dong M.;Rosen M.J.;Vinks A.A. (02-11-2020. ) Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric .Inflammatory Bowel Diseases, , 26 (3 ) ,429-439 More Information
Emoto C.;Hahn D.;Euteneuer J.;Mizuno T.;Vinks A.;Fukuda T. (02-01-2020. ) Next Challenge From the Variance in Individual Physiologically-Based Pharmacokinetic Model-Predicted.Clinical Pharmacology and Therapeutics, , 107 (2 ) ,319-320 More Information
Mizuno T.;Dong M.;Taylor Z.L.;Ramsey L.B.;Vinks A.A. (01-01-2020. ) Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient c.British Journal of Clinical Pharmacology, , More Information
Tang Girdwood S.C.;Mizuno T.;Krallman K.A.;Benken L.A.;Stoneman E.M.;Yunger T.M.;Wong H.R.;Vinks A.A.;Kaplan J.M. (01-01-2020. ) Route of oseltamivir administration affects metabolite concentrations in critically ill children.Pediatric Infectious Disease Journal, , 1224-1227 More Information
Taylor Z.L.;Mizuno T.;Punt N.C.;Baskaran B.;Navarro Sainz A.;Shuman W.;Felicelli N.;Vinks A.A.;Heldrup J.;Ramsey L.B. (01-01-2020. ) MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to In.Clinical Pharmacology and Therapeutics, , More Information
Vinks A.A.;Punt N.C.;Menke F.;Kirkendall E.;Butler D.;Duggan T.J.;Cortezzo D.M.E.;Kiger S.;Dietrich T.;Spencer P.;Keefer R.;Setchell K.D.R.;Zhao J.;Euteneuer J.C.;Mizuno T.;Dufendach K.R. (01-01-2020. ) Electronic Health Record–Embedded Decision Support Platform for Morphine Precision Dosing in Neonate.Clinical Pharmacology and Therapeutics, , 107 (1 ) ,186-194 More Information
McGann P.T.;Niss O.;Dong M.;Marahatta A.;Howard T.A.;Mizuno T.;Lane A.;Kalfa T.A.;Malik P.;Quinn C.T.;Ware R.E.;Vinks A.A. (08-01-2019. ) Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for y.American Journal of Hematology, , 94 (8 ) ,871-879 More Information
Mizuno T.;Gist K.M.;Gao Z.;Wempe M.F.;Alten J.;Cooper D.S.;Goldstein S.L.;Vinks A.A. (06-01-2019. ) Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infant.Clinical Pharmacokinetics, , 58 (6 ) ,793-803 More Information
Brunet M.;Van Gelder T.;Åsberg A.;Haufroid V.;Hesselink D.;Langman L.;Lemaitre F.;Marquet P.;Seger C.;Shipkova M.;Vinks A.;Wallemacq P.;Wieland E.;Woillard J.;Barten M.;Budde K.;Colom H.;Dieterlen M.;Elens L.;Johnson-Davis K.;Kunicki P.;Macphee I.;Masuda S.;Mathew B.;Millán O.;Mizuno T.;Moes D.;Monchaud C.;Noceti O.;Pawinski T.;Picard N.;Van Schaik R.;Sommerer C.;Vethe N.;De Winter B.;Christians U.;Bergan S. (06-01-2019. ) Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report.Therapeutic Drug Monitoring, , 41 (3 ) ,261-307 More Information
Ramsey L.;Mizuno T.;Vinks A.;O'Brien M. (05-01-2019. ) Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving .Pediatric Blood and Cancer, , 66 (5 ) , More Information
Hahn D.;Emoto C.;Euteneuer J.;Mizuno T.;Vinks A.;Fukuda T. (03-01-2019. ) Influence of OCT1 Ontogeny and Genetic Variation on Morphine Disposition in Critically Ill Neonates:.Clinical Pharmacology and Therapeutics, , 105 (3 ) ,761-768 More Information
Mizuno T.;O'Brien M.;Vinks A. (02-01-2019. ) Significant effect of infection and food intake on sirolimus pharmacokinetics and exposure in pediat.European Journal of Pharmaceutical Sciences, , 128 ,209-214 More Information
Boucher A.;Mizuno T.;Vinks A.;Goldstein S.;Tiao G.;Geller J. (01-01-2019. ) Dose modifications and pharmacokinetics of adjuvant cisplatin monotherapy while on hemodialysis for .Pediatric Blood and Cancer, , 66 (1 ) , More Information
Kaplan J.M.;Zingarelli B.;Krallman K.;Tang Girdwood S.;Lagory D.;Mizuno T.;Fei L.;Wong H.R.;Vinks A.A. (11-01-2018. ) Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with .Intensive Care Medicine, , 44 (11 ) ,2006-2008 More Information
Dong M.;McGann P.;Mizuno T.;Ware R.;Vinks A. (07-01-2018. ) Model-based dosing with concentration feedback as an integral part of personalized hydroxycarbamide .British Journal of Clinical Pharmacology, , 84 (7 ) ,1410-1412 More Information
Gist K.;Cooper D.;Wrona J.;Faubel S.;Altmann C.;Gao Z.;Marino B.;Alten J.;Hock K.;Mizuno T.;Vinks A.;Joy M.;Wempe M.;Bennett M.;Goldstein S. (04-01-2018. ) Acute Kidney Injury Biomarkers Predict an Increase in Serum Milrinone Concentration Earlier Than Ser.Therapeutic Drug Monitoring, , 40 (2 ) ,186-194 More Information
Mizuno T.;Emoto C.;Fukuda T.;Hammill A.;Adams D.;Vinks A. (11-15-2017. ) Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies.European Journal of Pharmaceutical Sciences, , 109 ,S124-S131 More Information
Alloway R.R.;Vinks A.A.;Fukuda T.;Mizuno T.;King E.C.;Zou Y.;Jiang W.;Woodle E.S.;Tremblay S.;Klawitter J.;Klawitter J.;Christians U. (11-01-2017. ) Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A.PLoS Medicine, , 14 (11 ) , More Information
Dong M.;Mizuno T.;Vinks A. (09-01-2017. ) Opportunities for model-based precision dosing in the treatment of sickle cell anemia.Blood Cells, Molecules, and Diseases, , 67 ,143-147 More Information
Mizuno T.;Fukuda T.;Emoto C.;Mobberley-Schuman P.;Hammill A.;Adams D.;Vinks A. (08-01-2017. ) Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infan.Pediatric Blood and Cancer, , 64 (8 ) , More Information
Faircloth J.M.;Miner K.M.;Alsaied T.;Nelson N.;Ciambarella J.;Mizuno T.;Palumbo J.S.;Vinks A.A.;Veldtman G.R. (07-01-2017. ) Time in therapeutic range as a marker for thrombotic and bleeding outcomes in Fontan patients.Journal of Thrombosis and Thrombolysis, , 44 (1 ) ,38-47 More Information
Diwan T.;Lichvar A.;Leino A.;Vinks A.;Christians U.;Shields A.;Cardi M.;Fukuda T.;Mizuno T.;Kaiser T.;Woodle E.;Alloway R. (06-01-2017. ) Pharmacokinetic and pharmacogenetic analysis of immunosuppressive agents after laparoscopic sleeve g.Clinical Transplantation, , 31 (6 ) , More Information
Balyan R.;Zhang X.;Chidambaran V.;Martin L.;Mizuno T.;Fukuda T.;Vinks A.;Sadhasivam S. (05-01-2017. ) OCT1 genetic variants are associated with postoperative morphine-related adverse effects in children.Pharmacogenomics, , 18 (7 ) ,621-629 More Information
Ramsey L.;Mizuno T.;Vinks A.;Margolis P. (03-01-2017. ) Learning Health Systems as Facilitators of Precision Medicine.Clinical Pharmacology and Therapeutics, , 101 (3 ) ,359-367 More Information
Chidambaran V.;Venkatasubramanian R.;Zhang X.;Martin L.;Niu J.;Mizuno T.;Fukuda T.;Meller J.;Vinks A.;Sadhasivam S. (03-01-2017. ) ABCC3 genetic variants are associated with postoperative morphine-induced respiratory depression and.Pharmacogenomics Journal, , 17 (2 ) ,162-169 More Information
Mizuno T.;Fukuda T.;Christians U.;Perentesis J.;Fouladi M.;Vinks A. (01-01-2017. ) Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: .British Journal of Clinical Pharmacology, , 83 (5 ) ,1097-1107 More Information
Cabrera-Salcedo C.;Mizuno T.;Tyzinski L.;Andrew M.;Vinks A.A.;Frystyk J.;Wasserman H.;Gordon C.M.;Hwa V.;Backeljauw P.;Dauber A. (01-01-2017. ) Pharmacokinetics of IGF-1 in PAPP-A2-deficient patients, growth response, and effects on glucose and.Journal of Clinical Endocrinology and Metabolism, , 102 (12 ) ,4568-4577 More Information
Chidambaran V.;Pilipenko V.;Spruance K.;Venkatasubramanian R.;Niu J.;Fukuda T.;Mizuno T.;Zhang K.;Kaufman K.;Vinks A.;Martin L.;Sadhasivam S. (01-01-2017. ) Fatty acid amide hydrolase-morphine interaction influences ventilatory response to hypercapnia and p.Pharmacogenomics, , 18 (2 ) ,143-156 More Information
Emoto C.;Fukuda T.;Mizuno T.;Schniedewind B.;Christians U.;Adams D.;Vinks A. (08-01-2016. ) Characterizing the developmental trajectory of sirolimus clearance in neonates and infants.CPT: Pharmacometrics and Systems Pharmacology, , 5 (8 ) ,411-417 More Information
Dong M.;McGann P.;Mizuno T.;Ware R.;Vinks A. (04-01-2016. ) Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in.British Journal of Clinical Pharmacology, , 81 (4 ) ,742-752 More Information
Hahn A.;Fukuda T.;Hahn D.;Mizuno T.;Frenck R.;Vinks A. (04-01-2016. ) Pharmacokinetics and pharmacogenomics of ?-lactam-induced neutropenia.Pharmacogenomics, , 17 (6 ) ,547-559 More Information
Nehus E.;Mizuno T.;Cox S.;Goldstein S.;Vinks A. (03-01-2016. ) Pharmacokinetics of meropenem in children receiving continuous renal replacement therapy: Validation.Journal of clinical pharmacology, , 56 (3 ) ,291-297 More Information
Wiles J.;Isemann B.;Mizuno T.;Tabangin M.;Ward L.;Akinbi H.;Vinks A. (12-01-2015. ) Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study.The Journal of pediatrics, , 167 (6 ) ,1214-1220.e3 More Information
Gist K.M.;Mizuno T.;Goldstein S.L.;Vinks A. (01-01-2015. ) Retrospective evaluation of milrinone pharmacokinetics in children with kidney injury.Therapeutic Drug Monitoring, , 37 (6 ) ,792-796 More Information
Emoto C.;Fukuda T.;Mizuno T.;Cox S.;Schniedewind B.;Christians U.;Widemann B.C.;Fisher M.J.;Weiss B.;Perentesis J.;Vinks A.A. (01-01-2015. ) Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1.Therapeutic Drug Monitoring, , 37 (3 ) ,395-399 More Information
Fukudo M.;Ito T.;Mizuno T.;Shinsako K.;Hatano E.;Uemoto S.;Kamba T.;Yamasaki T.;Ogawa O.;Seno H.;Chiba T.;Matsubara K. (02-01-2014. ) Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepat.Clinical Pharmacokinetics, , 53 (2 ) ,185-196 More Information
Venkatasubramanian R.;Fukuda T.;Niu J.;Mizuno T.;Chidambaran V.;Vinks A.;Sadhasivam S. (01-01-2014. ) ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children.Pharmacogenomics, , 15 (10 ) ,1297-1309 More Information
Mizuno T.;Fukuda T.;Masuda S.;Uemoto S.;Matsubara K.;Inui K.;Vinks A. (01-01-2014. ) Developmental trajectory of intestinal MDR1/ABCB1 mRNA expression in children.British Journal of Clinical Pharmacology, , 77 (5 ) ,910-912 More Information
Ishii T.;Hatano E.;Taura K.;Mizuno T.;Kawai T.;Fukudo M.;Katsura T.;Uemoto S. (01-01-2014. ) Sorafenib in a hepatocellular carcinoma patient with end-stage renal failure: A pharmacokinetic stud.Hepatology Research, , 44 (6 ) ,685-688 More Information
Mizuno T.;Fukudo M.;Fukuda T.;Terada T.;Dong M.;Kamba T.;Yamasaki T.;Ogawa O.;Katsura T.;Inui K.I.;Vinks A.A.;Matsubara K. (01-01-2014. ) The Effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal .Therapeutic Drug Monitoring, , 36 (3 ) ,310-316 More Information
Kunimatsu S.;Mizuno T.;Fukudo M.;Katsura T. (08-01-2013. ) Effect of P-glycoprotein and breast cancer resistance protein inhibition on the pharmacokinetics of .Drug Metabolism and Disposition, , 41 (8 ) ,1592-1597 More Information
Fukuda T.;Chidambaran V.;Mizuno T.;Venkatasubramanian R.;Ngamprasertwong P.;Olbrecht V.;Esslinger H.;Vinks A.;Sadhasivam S. (01-01-2013. ) OCT1 genetic variants influence the pharmacokinetics of morphine in children.Pharmacogenomics, , 14 (10 ) ,1141-1151 More Information
Togashi Y.;Masago K.;Masuda S.;Mizuno T.;Fukudo M.;Ikemi Y.;Sakamori Y.;Nagai H.;Kim Y.;Katsura T.;Mishima M. (09-01-2012. ) Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung ca.Cancer Chemotherapy and Pharmacology, , 70 (3 ) ,399-405 More Information
Mizuno T.;Fukudo M.;Terada T.;Kamba T.;Nakamura E.;Ogawa O.;Inui K.I.;Katsura T. (01-01-2012. ) Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacoki.Drug Metabolism and Pharmacokinetics, , 27 (6 ) ,631-639 More Information
Shinsako K.;Mizuno T.;Terada T.;Watanabe J.;Kamba T.;Nakamura E.;Ogawa O.;Inui K.I. (10-01-2010. ) Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: A case study.International Journal of Clinical Oncology, , 15 (5 ) ,512-514 More Information
Mizuno T.;Terada T.;Kamba T.;Fukudo M.;Katsura T.;Nakamura E.;Ogawa O.;Inui K. (02-06-2010. ) ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcino.Annals of Oncology, , 21 (6 ) ,1382-1383 More Information
Tsuda M.;Terada T.;Mizuno T.;Katsura T.;Shimakura J.;Inui K. (06-01-2009. ) Targeted disruption of the multidrug and toxin extrusion 1 (Mate1) gene in mice reduces renal secret.Molecular Pharmacology, , 75 (6 ) ,1280-1286 More Information
Mizuno T.;Mohri K.;Nasu S.;Danjo K.;Okamoto H. (03-04-2009. ) Dual imaging of pulmonary delivery and gene expression of dry powder inhalant by fluorescence and bi.Journal of Controlled Release, , 134 (2 ) ,149-154 More Information
Kodawara T.;Mizuno T.;Taue H.;Hashida T.;Yano I.;Katsura T.;Inui K. (03-01-2009. ) Evaluation of stability of temozolomide in solutions after opening the capsule.Yakugaku Zasshi, , 129 (3 ) ,353-357 More Information